In one aspect, a method of treating a subject having or at risk of having a tumor generally includes administering to the subject an amount of a PKC-NFkB axis inhibitor effective to ameliorate at least one symptom or clinical PMA sign of the tumor. In another aspect, a method of treating a subject having a tumor generally includes confirming that APOBEC3B is present in cells of the tumor and administering to the subject an amount of a PKC-NFkB axis inhibitor effective to decrease APOBEC3B in the cells of the tumor.
